Glenmark Pharmaceuticals Q2 FY27 Share Price & Earnings Call Analysis
Part of: Nifty Midcap 150 · Nifty Healthcare Index · Nifty Pharma · Nifty Midcap 50 · NIFTY Midcap 100 · Nifty 200 · +4 more
- Market cap
- ₹74,984 Cr
- P/E
- 37.01
- ROE
- 23.56%
- PEG
- 0.61
- Price to sales
- 4.70
- Debt to equity
- 0.13
- 52W high / low
- ₹2,677 / ₹1,817
- Sales growth (5Y)
- 9.19%
- EBITDA margin
- 20.71%
- Net profit margin
- 13.43%
- Promoter holding
- 46.65%
- Sales (last year)
- ₹15,937 Cr
Guidance scorecard · Q2 FY27 call
What Glenmark Pharmaceuticals's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
10–20%- Glenmark expects consistent 15%-20% growth in emerging markets over the next few years.
- Oncology franchise projected to contribute significantly starting FY 2028, with peak sales estimated at $100-$150 million by FY 2030, and $400-$500 million by 2035-36 (excluding ISB 2001).
- RYALTRIS sales forecasted to reach $130-$140 million this year, growing at 30%-40% annually, with broad-based growth across multiple markets including U.S., Brazil, and China.
- Oncology products anticipated to generate $30-$40 million incremental sales next year, with margins well above the company average.
- U.S. growth driven by respiratory product launches (MDI, DPI filings annually) and injectables, including Monroe portfolio.
2 more points from Glenmark Pharmaceuticals's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
Up 0–2%See what Glenmark Pharmaceuticals said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Glenmark made significant investments in H1 FY27, including strategic field force expansion across various markets, especially in oncology and emerging markets.
- Total capex during Q2 was about INR262.1 crores (INR170 crores tangible, INR92 crores intangible).
- Future investments include continued spend in the U.S. to build up the respiratory and injectables portfolio.
- Oncology franchise investments have been front-loaded in H1, expected to yield results in H2 and beyond.
2 more points from Glenmark Pharmaceuticals's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
PlannedSee what Glenmark Pharmaceuticals said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
- Financial performance, revenue growth, and cash flow.
- Product launches and pipeline updates, including respiratory products and oncology assets.
- Strategic investments, field force expansions, and ongoing collaborations (e.g., ISB 2001 with AbbVie).
2 more points from Glenmark Pharmaceuticals's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Glenmark Pharmaceuticals.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingGlenmark Pharmaceuticals announcements
All announcements →- Financial resultsMajor developmentGlenmark Pharmaceuticals reports audited Q4 and FY26 results with dividend recommendation
Financials of Glenmark Pharmaceuticals
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Glenmark Pharmaceuticals
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.64% | 46.64% | 46.65% | 46.65% | 46.65% | 46.65% |
| FIIs + | 23.71% | 21.38% | 20.98% | 23.05% | 23.51% | 23.15% | 20.62% | 20.73% | 19.20% | 20.35% | 20.89% | 21.51% |
| DIIs + | 10.92% | 13.36% | 13.93% | 13.21% | 13.85% | 14.60% | 17.64% | 18.61% | 20.09% | 19.28% | 18.60% | 17.63% |
| Government + | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public + | 18.70% | 18.58% | 18.42% | 17.06% | 15.96% | 15.56% | 15.05% | 13.97% | 14.02% | 13.70% | 13.81% | 14.17% |
| No. of Shareholders | 2,09,931 | 1,99,451 | 1,92,630 | 1,93,949 | 1,95,059 | 1,92,724 | 1,90,210 | 1,98,789 | 2,01,584 | 1,96,105 | 2,11,418 | 2,08,414 |
Financials of Glenmark Pharmaceuticals
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 | 4,247 |
| YoY Sales growth | +6% | -19% | +2% | +7% | +7% | +35% | +6% | +1% | +76% | +15% | +16% | +23% | -30% |
| Expenses + | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 | 3,384 |
| Operating Profit | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 | 864 |
| OPM % | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% | 20% |
| Other Income + | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 | -281 |
| Interest | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 | 64 |
| Depreciation | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 | 180 |
| Profit before tax | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 | 338 |
| Tax % | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% | 22% |
| Net Profit + | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 | 264 |
| EPS in Rs | -2.90 | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 | 9.35 |
Financials of Glenmark Pharmaceuticals
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 15,937 |
| Sales growth | +9% | +15% | +20% | -0% | +9% | +8% | +3% | +12% | -6% | +2% | +13% | +27% | -0% |
| Expenses + | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 9,948 | 10,618 | 10,970 | 12,410 | 12,636 |
| Operating Profit | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 1,635 | 1,195 | 2,351 | 4,572 | 3,301 |
| OPM % | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 14% | 10% | 18% | 27% | 21% |
| Other Income + | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -10 | 336 | -259 | -1,805 | -540 |
| Interest | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 202 |
| Depreciation | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 656 |
| Profit before tax | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 707 | 434 | 1,399 | 1,985 | 1,903 |
| Tax % | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 47% | 430% | 25% | 31% | |
| Net Profit + | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,451 |
| EPS in Rs | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 | 51.43 |
| Dividend Payout % | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% | -5% | 7% | 10% |
Financials of Glenmark Pharmaceuticals
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 10,484 | 11,184 |
| Borrowings + | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,608 | 1,231 | 2,473 | 594 | 1,407 |
| Other Liabilities + | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,289 | 5,279 | 4,669 | 8,801 | 8,780 |
| Total Liabilities | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 | 21,400 |
| Fixed Assets + | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,487 | 5,915 | 6,385 |
| CWIP | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 | 835 | 909 | 599 |
| Investments | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 | 42 |
| Other Assets + | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 12,715 | 8,697 | 10,613 | 13,041 | 14,373 |
| Total Assets | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 | 21,400 |
Financials of Glenmark Pharmaceuticals
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | -828 | 3,445 |
| Cash from Investing Activity + | -712 | -950 | -1,001 | -1,003 | -883 | -774 | -662 | -316 | -515 | 4,387 | 58 | -1,237 |
| Cash from Financing Activity + | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 | 787 | -2,709 |
| Net Cash Flow | -31 | 93 | 199 | 177 | -297 | 174 | 28 | 272 | 32 | 215 | 17 | -501 |
| Free Cash Flow | -56 | -544 | -76 | 625 | 712 | 616 | 456 | 320 | 75 | -1,162 | -1,576 | 2,090 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 66% | 57% | 67% | 124% | 111% | 109% | 79% | 72% | 77% | 65% | -6% | 92% |
Financials of Glenmark Pharmaceuticals
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 | 107 |
| Inventory Days | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 | 264 |
| Days Payable | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 256 | 288 |
| Cash Conversion Cycle | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 90 | 83 |
| Working Capital Days | 47 | 51 | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 | 81 |
| ROCE % | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% | 40% |
Guidance history
How Glenmark Pharmaceuticals's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 10–20% | Up 0–2% | Planned | Planned | — |
| Q1 FY27 call → | 10–20% | Flat | Planned | None planned | — |
| Q4 FY26 call → | 20–40% | Flat | Planned | — | — |
| Q3 FY26 call → | 10–20% | Up 2%+ | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
78 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,932 stocks |
|---|---|---|
| Last 12 months | +47.3% | 83% |
| Last 6 months | +17.5% | 69% |
| Last 3 months | +16.9% | 86% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,932 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Glenmark Pharmaceuticals: 0.4 × 83 + 0.4 × 69 + 0.2 × 86 = 78.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 11 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Glenmark Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alkem Lab (Q2 FY27)
Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres
- Caplin Point Laboratories Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor
- Ortin Global (Q2 FY27)
This represents a year-on-year increase of Rs 1.74 lakhs (approximately 124.3% increase). Key results statement takeaways from Ortin Global Ltd's Q2 FY27 result
- Bal Pharma (Q2 FY27)
Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…
